Wieser Boesiger
Fakultäten » Medizinische Fakultät » Neurologie, Klinik für » Prof. Dr. Heinz-Gregor Wieser (emeritiert) » Wieser Boesiger
Completed research project
| Title / Titel | Effects of vigabatrin on brain GABA+/CR signals in patients with epilepsy monitored by 1H-NMR-spectroscopy: responder characteristics. | ||||||
|---|---|---|---|---|---|---|---|
| Abstract (PDF, 14 KB) | |||||||
| Summary / Zusammenfassung | Vigabatrin (VGB) is a new antiepileptic drug that increases the human brain -aminobutyric acid (GABA) level by irreversibly inhibiting GABA transaminase. Although some patients respond to VGB with a significant seizure reduction, others do not. The aim of this study was to identify possible responders before or in an early phase of VGB treatment by measuring the GABA and homocarnosine contaminated with macromolecules/creatine and phosphocreatine ratio (GABA+/Cr) signal by means of proton-nuclear magnetic resonance (1H NMR) spectroscopy. Responders to VGB were characterized by a lower ipsilateral baseline GABA+/Cr signal and a steeper increase during VGB treatment. However, it was not possible to predict the duration of the response (full versus partial responder) with these criteria. | ||||||
| Publications / Publikationen | Mueller SG, Weber OM, Duc CO, Meier D, Russ W, Boesiger P, Wieser HG.Effects of vigabatrin on brain GABA+/Cr signals in focus-distant and focus-near brain regions monitored by 1H-NMR spectroscopy. Eur J Neurol 2003;10:45-52Mueller SG, Weber OM, Duc CO, Weber B, Meier D, Russ W, Boesiger P, Wieser HG. Effects of vigabatrin on brain GABA+/CR signals in patients with epilepsy monitored by 1H-NMR-spectroscopy: responder characteristics. Epilepsia 2001;42:29-40Mueller SG, Weber OM, Boesiger P, Wieser HG. Influence of pyridoxal 5'-phosphate alone and in combination with vigabatrin on brain GABA measured by 1H-NMR-spectroscopy. Brain Res Bull 2001;55:555-60 | ||||||
| Keywords / Suchbegriffe | GABA, MR-spectroscopy, epilepsy, vigabatrin, responder, pyridoxal-phosphate | ||||||
| Project leadership and contacts / Projektleitung und Kontakte |
|
||||||
| Funding source(s) / Unterstützt durch |
Private Sector (e.g. Industry), Others Höchst Pharma |
||||||
| Duration of Project / Projektdauer | Jan 1997 to Jan 1999 |